As CAR-T therapy gains momentum in treating cancers, we bear a sense of a time-bound mission to guard its safety, while exploring its unlimited potential in curing a wide spectrum of diseases. Currently, we are developing non-viral based autologous CAR-T therapy, and we will expand it to non-viral based genetically modified allogeneic CAR-T, TCR-T or CAR-NK, even extended to gene therapies beyond immune-related approaches. We hope this summary conveys our vision and passion in finding cures for cancer and inspires prospective investors to join us in this exciting journey.

螢幕快照 2019-06-14 下午3.50.08.png